AstraZeneca Signs Blockbuster Deal With Ionis for TTR Amyloidosis Treatment December 8, 2021 Auto Bot News 0 AstraZeneca struck a deal worth up to more than $3.5 billion with Ionis Pharmaceuticals for the rights to develop and commercialize their transthyretin (TTR) amyloidosis treatment.